N/A
Completed N=57
The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder
Attention Deficit Disorder With Hyperactivity (ADHD)
Source: ClinicalTrials.gov NCT07041333 ↗
Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcomePrimary: Change in IL-6 Marker Level — 113.89; 103.45 ng/L — p=0.014
Summary
The aim of this study was to investigate the effect of treatment of ADHD with methylphenidate on neuroinflammation by examining the levels of Interleukin-6 (IL-6), S100B, Claudin-5 in serum samples of patients who were diagnosed with attention deficit hyperactivity disorder (ADHD) and started or planned to start methylphenidate for treatment as per routine, at month 0 before the initiation of methylphenidate treatment and at month 3 after the initiation of treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in IL-6 Marker Level |
113.89; 103.45 | 0.014 sig |
| PRIMARY Change in S100B Marker Level |
871.13; 758.13 | 0.018 sig |
| PRIMARY Change in the Level of Claudin-5 Marker |
206.52; 181.76 | 0.175 |
Eligibility Criteria
Inclusion Criteria
- According to DSM-5 TR, the participant must have a diagnosis of "Attention Deficit Hyperactivity Disorder" and have started/be planning to start routine methylphenidate treatment.
- The participant must be between 6 and 11 years of age.
- The participant must agree to participate in the study after being informed about it.
Exclusion Criteria
- The presence of a psychiatric disorder diagnosis other than Attention Deficit Hyperactivity Disorder
- Having a diagnosis of Attention Deficit Hyperactivity Disorder but not planning to start methylphenidate
- Being under 6 years of age or over 11 years of age
- Having organic brain damage, mental retardation, autism spectrum disorder, neurological disease, or a physical illness that affects neurocognitive functions
- History of alcohol and/or psychoactive substance use
- Presence of ongoing active infection, allergic disease, and chronic illness
- Previous use of psychiatric medication.
- Presence of chronic illness
- Regular use of medication
Data sourced from ClinicalTrials.gov (NCT07041333). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.